Russell Investments Group
CTKB icon

Russell Investments Group’s Cytek Biosciences CTKB Stock Holding History

Russell Investments Group’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.7M Buy
1,511,315
+151,415
+11% +$646K 0.01% 1322
2026
Q1 		$5.94M Buy
1,359,900
+358,773
+36% +$1.69M 0.01% 1261
2025
Q4 		$5.06M Buy
1,001,127
+841,614
+528% +$3.91M 0.01% 1321
2025
Q3 		$554K Buy
159,513
+131,718
+474% +$494K ﹤0.01% 2440
2025
Q2 		$94.5K Sell
27,795
-39,589
-59% -$132K ﹤0.01% 2832
2025
Q1 		$270K Buy
67,384
+39,582
+142% +$205K ﹤0.01% 2504
2024
Q4 		$180K Sell
27,802
-10,403
-27% -$62K ﹤0.01% 2563
2024
Q3 		$212K Buy
38,205
+29,845
+357% +$169K ﹤0.01% 2501
2024
Q2 		$46.6K Buy
8,360
+8,168
+4,254% +$49.1K ﹤0.01% 2778
2024
Q1 		$1.29K Buy
192
+71
+59% +$562 ﹤0.01% 3115
2023
Q4 		$1.1K Buy
+121
New +$762 ﹤0.01% 3054

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Russell Investments Group's CTKB Position: Q2 2026 in Review

Russell Investments Group increased its Cytek Biosciences (CTKB) stake by 11% in Q2 2026, buying an estimated $646K and bringing the position to 1,511,315 shares worth $6.7M. The position accounts for 0.01% of the portfolio, ranked #1322.

Russell Investments Group first reported a position in CTKB in Q4 2023 and has held it in 11 quarters since. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Russell Investments Group held 1,511,315 shares of Cytek Biosciences worth $6.7M as of Q2 2026.
  • Russell Investments Group bought 151,415 Cytek Biosciences shares in Q2 2026, an estimated $646K.
  • Cytek Biosciences made up 0.01% of Russell Investments Group's portfolio in Q2 2026, its #1322 holding.
  • Russell Investments Group first reported a position in Cytek Biosciences in Q4 2023 and has held it in 11 quarters since.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.